2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

4-7 September 2018
Lisbon, Portugal

Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), this multidisciplinary meeting will address the challenges, opportunities and current requirements for antimicrobial drug development for AMR. 



Bootcamp: Pre-clinical toxicology

Date: Tuesday 4 September 2018
Time: 13:00-15:00

Chair: Ursula Theuretzbacher, Founder and Director, Center for Anti-Infective Agents, Austria and consultant to GARDP


Round table discussion

Building the evidence base to inform AMR-related decision-making

Date: Tuesday 4 September 2018
Time: 13:00-15:00

Chair: John H. Rex, Chief Medical Officer, F2G, United Kingdom


  • Jeremy Knox, Policy and Advocacy Lead, Drug-Resistant Infections Programme, Wellcome Trust, UK
  • Kevin Krause, Senior Director, Corporate Development and Head of Microbiology, Achaogen, USA
  • Seamus O’Brien, R&D Director, GARDP, Switzerland
  • Evelina Tacconelli, Professor of Infectious Diseases, Head of the Division of Infectious Disease and Medical Director of the Comprehensive Infectious Diseases Center (CIDiC), University Hospital of Tübingen, Germany
  • Didem Torumkuney, Scientific Director, Infectious Diseases, GSK, Austria


More information: